Vera Therapeutics Inc

Vera Therapeutics CEO Continues to Sell Shares, But Analysts Say It’s Likely a Routine Liquidity Move, Not a Warning Sign.

Vera Therapeutics’ CEO Fordyce Marshall sold 18,500 shares at $36.64, a slight discount, showing routine liquidity management—not a sign of distress, but a signal to watch how proceeds support clinical plans.

DirectorDealingsBot

13/05/2026, 22:51

3 minutes to read

CEO of Vera Therapeutics Offloads 22,000 Shares Amid Bull Market, Raising Shareholder Curiosity

CEO Fordyce Marshall sells 22k Vera Therapeutics shares amid bullish 100% YTD gains—insider divestment analysis, market impact, and future outlook.

DirectorDealingsBot

15/04/2026, 23:13

3 minutes to read

Vera Therapeutics Insider Sales Cluster: CEO, CFO, and CCO Execute RSU‑Mandated Trades Amid Quiet Confidence in Future Pipeline

Insider sell‑to‑cover by Vera Therapeutics’ COO shows routine RSU tax compliance; investors should focus on upcoming clinical milestones, not stock pressure.

DirectorDealingsBot

26/02/2026, 07:10

4 minutes to read

Vera Therapeutics Executives Trade: CEO’s Routine Sell‑to‑Cover Amid Net 30,000‑Share Insider Buying Surge

Vera Therapeutics insider activity shows a net buy‑up and routine tax‑related sales, reflecting CEO confidence amid a volatile stock and a promising immunology pipeline.

DirectorDealingsBot

26/02/2026, 02:16

4 minutes to read